OTC Drug Advertising Outpaces Rx Direct-To-Consumer Spending At J&J, Schering
This article was originally published in The Pink Sheet Daily
Executive Summary
J&J spent 40% more on OTC ads compared to Rx direct-to-consumer spots during the first nine months. Schering's OTC spending was more than triple expenditures for its prescription consumer advertising due to the Claritin switch.